Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05180357 · ClinicalTrials.gov registry record
RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps.
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 273
- Enrollment target
NCT05180357: Completed study, sponsored by AstraZeneca.
NCT05180357 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 273 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05180357 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 273 participants
- Enrollment target
Study Summary
The purpose of this observational study is to describe the population of patients with SEA + NP who have been prescribed FASENRA and assess available clinical outcomes for both NP and asthma.
Primary Outcome
To describe baseline demographics, clinical characteristics, and background treatments, as well as PROs (patient-reported outcomes) for asthma control and HRQoL(health-related quality of life), asthma exacerbation, and healthcare resource utilization.
Interventions
- OTHER FASENRA(benralizumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 273 participants |
| Start Date | 2021-11-23 |
| Est. Completion | 2022-10-28 |
What the finished NCT05180357 record still lists
NCT05180357 is an observational study that tracks outcomes without assigning an intervention. The registered 273 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which FASENRA(benralizumab) is the first listed.
NCT05180357 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05180357 about?
NCT05180357 is a clinical study titled "RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps.". The purpose of this observational study is to describe the population of patients with SEA + NP who have been prescribed FASENRA and assess available clinical outcomes for both NP and asthma.
What is the current status of trial NCT05180357?
This trial is currently completed. The enrollment target is 273 participants. The study started on 2021-11-23. Estimated completion is 2022-10-28.
What interventions are being tested in trial NCT05180357?
The interventions under investigation include: FASENRA(benralizumab) (OTHER).
Who is sponsoring clinical trial NCT05180357?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07229430 · 273 participants · NA
Safety and Effectiveness Evaluation of the High-intensity Focused Ultrasound Device for Lifting Lax Submental and Neck Tissue
- NCT03808922 · 274 participants · Phase 3
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
- NCT04573504 · 274 participants · Phase 4
Antibiotics for Severe Perineal Laceration to Prevent Infection Following Repair
- NCT05289557 · 274 participants · Phase 3
The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI